LPAR3 and hepatocellular carcinoma: Given that healthy, non-parenchymal cells in the liver express LPAR1 and/or LPAR3 at low levels, this raises the possibility of developing selective therapies against LPAR1 and/or LPAR3 to slow or regress HCC progression.